Pepijn W. A. Thomas
Radboud University Nijmegen
PathophysiologyRisk assessmentInternal medicineIntensive care medicineProspective cohort studyDe-escalationBudesonideVedolizumabAzathioprineInfliximabMercaptopurineSummary of Product CharacteristicsInflammatory bowel diseaseEndoscopyTofacitinibUstekinumabDiseaseCrohn's diseasePatient-reported outcomeQuality of life (healthcare)AdalimumabUlcerative colitisInfusion reactionLeukocyte L1 Antigen ComplexInfusion ProcedureDrug reactionIn patientHealthcare providersInduction doseOutcome measuresPharmacovigilancePopulation studyThiopurine methyltransferaseMedicineCumulative incidenceGastroenterology
9Publications
1H-index
5Citations
Publications 9
Newest
#1Pepijn W. A. Thomas (Radboud University Nijmegen)H-Index: 1
#2Tessa E H Römkens (Bosch)H-Index: 13
Last. Frank Hoentjen (Radboud University Nijmegen)H-Index: 16
view all 8 authors...
BACKGROUND Only limited data is available on the extent and burden of adverse drug reactions (ADRs) to biological therapy in inflammatory bowel disease (IBD) patients in daily practice, especially from a patient's perspective. OBJECTIVE The aim of this study was to systematically assess patient-reported ADRs during biological therapy in IBD patients and compare these with healthcare provider (HCP)-reported ADRs. METHODS This multicentre, prospective, event monitoring study enrolled IBD patients ...
Source
Source
Source
Source
#1Pepijn W. A. Thomas (Radboud University Nijmegen)H-Index: 1
#2Rachel L. WestH-Index: 16
view all 9 authors...
Purpose To assess the agreement between patient-reported and health care provider-reported medical information in inflammatory bowel disease (IBD). Methods This multicentre, prospective, event monitoring study enrolled adult Crohn's disease (CD) and ulcerative colitis (UC) patients treated with a biological in four medical centres in the Netherlands. At two-monthly intervals, patients completed questionnaires on biological use, combination therapy and indication. The patient-reported information...
Source
#1Eline L. GiraudH-Index: 1
#2Ibdream registry (Radboud University Nijmegen)
Last. Frank Hoentjen (Radboud University Nijmegen)H-Index: 16
view all 11 authors...
INTRODUCTION Inflammatory bowel disease (IBD) frequently requires chronic immunosuppressive treatment and active involvement from patients during treatment decision making. Information about the risk of developing adverse drug reactions (ADRs) to IBD therapies is required in this process. OBJECTIVE The aim of this study was to describe the ADRs reported in IBD patients from real-world data, using the Dutch nationwide IBDREAM registry, and compare the occurrence and cumulative incidences with the...
Source
#1Michiel E. de Jong (Radboud University Nijmegen)H-Index: 3
#2Erik Taal (UT: University of Twente)H-Index: 51
Last. Maurice G. RusselH-Index: 38
view all 9 authors...
There is a need for easy-to-use patient-reported outcome measures (PROMS) in inflammatory bowel disease (IBD) practice. The ‘IBD-control’ is a short IBD-specific questionnaire capturing disease con...
Source
#1Pepijn W. A. Thomas (Radboud University Nijmegen)H-Index: 1
#2Gerben FerwerdaH-Index: 30
Last. Frank Hoentjen (Radboud University Nijmegen)H-Index: 16
view all 4 authors...
Recently, ustekinumab has been approved for the treatment of Crohn's disease and ulcerative colitis. Treatment is started with an intravenous induction dose, followed by a subcutaneous dosage. We present three patients with therapy-refractory Crohn's disease, who experienced an immediate infusion reaction to intravenous administration of ustekinumab. In two of these patients a subsequent reaction to subcutaneous injections occurred. Clinical features and pathophysiology are discussed.
1 CitationsSource
#1Pepijn W. A. Thomas (Radboud University Nijmegen)H-Index: 1
#2Rachel WestH-Index: 6
Last. Frank Hoentjen (Radboud University Nijmegen)H-Index: 16
view all 8 authors...
1 CitationsSource